Eganelisib: A Promising Treatment for Various Cancers

Table of Contents

• What is Eganelisib?
• How Eganelisib Works
• Medical Conditions Treated
• Eganelisib in Combination Therapies
• Clinical Trials
• Safety and Side Effects
• Administration

What is Eganelisib?

Eganelisib (also known as IPI-549) is a first-in-class, oral medication that is being studied for the treatment of various types of cancer ^[1]. It belongs to a class of drugs that selectively inhibits an enzyme called phosphoinositide-3-kinase gamma (PI3K-gamma) ^[4].

Eganelisib is currently being investigated in multiple clinical trials to evaluate its effectiveness and safety, both as a standalone treatment (monotherapy) and in combination with other cancer medications ^[2].

How Eganelisib Works

Eganelisib works by targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of PI3K-gamma ^[4]. In simpler terms, the drug helps to reprogram certain immune cells (macrophages) in the tumor microenvironment.

This reprogramming can potentially help your immune system better recognize and attack cancer cells. By targeting the PI3K-gamma pathway, eganelisib aims to overcome one of the mechanisms by which cancer cells evade the immune system ^[2].

Medical Conditions Treated

Based on ongoing clinical trials, eganelisib is being investigated for the treatment of several types of cancer:

• Blood Cancers:
  • Acute Myeloid Leukemia (AML) - a type of cancer that affects the blood and bone marrow ^[1]
  • Higher-risk Myelodysplastic Syndromes (HR-MDS) - a group of disorders characterized by poorly formed or dysfunctional blood cells ^[1]
• Solid Tumors:
  • Advanced Urothelial Carcinoma (bladder cancer) ^[3]
  • Triple-Negative Breast Cancer (TNBC) ^[4]
  • Renal Cell Carcinoma (kidney cancer) ^[4]
  • Non-small Cell Lung Cancer ^[2]
  • Melanoma (skin cancer) ^[2]
  • Squamous Cell Cancer of the Head and Neck ^[2]
  • Adrenocortical Carcinoma ^[2]
  • Mesothelioma ^[2]

The drug is particularly being studied in patients whose cancer has relapsed (come back) or is refractory (not responding to previous treatments) ^[1].

Eganelisib in Combination Therapies

Eganelisib is being studied both as a standalone treatment and in combination with other cancer medications. Some of the combination therapies include:

• Eganelisib + Cytarabine: For patients with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes ^[1]
• Eganelisib + Nivolumab (Opdivo): For patients with various advanced solid tumors, including urothelial carcinoma ^{[2] [3]}
• Eganelisib + Atezolizumab (Tecentriq) + nab-paclitaxel (Abraxane): For patients with triple-negative breast cancer ^[4]
• Eganelisib + Atezolizumab (Tecentriq) + Bevacizumab (Avastin): For patients with renal cell carcinoma ^[4]

These combinations are designed to potentially enhance the effectiveness of each drug and provide better outcomes for patients ^[4].

Clinical Trials

Several clinical trials are currently underway to evaluate eganelisib:

• NCT06533761: A Phase 1b study evaluating the safety and tolerability of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes ^[1]
• NCT02637531 (IPI-549-01): A Phase 1/1b dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of eganelisib monotherapy and in combination with nivolumab in subjects with advanced solid tumors ^[2]
• NCT03980041 (MARIO-275): A Phase 2 study to evaluate the efficacy and safety of nivolumab administered in combination with eganelisib compared to nivolumab monotherapy in the treatment of patients with immune therapy-naïve, advanced urothelial carcinoma ^[3]
• NCT03961698 (MARIO-3): A Phase 2 study to evaluate efficacy and safety of eganelisib administered in combination with front-line treatment regimens in patients with locally advanced and/or metastatic triple-negative breast cancer or renal cell carcinoma ^[4]

These trials are examining various aspects of the drug, including:

• Finding the right dose (dose-escalation and dose-optimization) ^[1]
• Understanding how the drug moves through the body (pharmacokinetics) ^[2]
• Studying how the drug affects the body (pharmacodynamics) ^[2]
• Measuring the drug's effectiveness against cancer (anti-tumor efficacy) ^[1]
• Assessing safety and side effects ^[3]

Safety and Side Effects

As with any medication under investigation, the safety profile and potential side effects of eganelisib are being carefully studied in clinical trials. Common measures being tracked include:

• Incidence and severity of adverse events (AEs) ^[1]
• Dose-limiting toxicities (DLTs) ^[1]
• Changes in vital signs (pulse rate, temperature, respiration rate, blood pressure) ^{[3] [4]}
• Changes in electrocardiograms (ECGs) ^{[3] [4]}
• Changes in laboratory values, including thyroid function tests ^[3]

The trials are designed to identify any safety concerns and determine the most appropriate dosage for patients ^[1].

Administration

Eganelisib is an oral medication, typically administered as a daily dose in capsule form ^{[2] [4]}. The specific dosage can vary depending on the clinical trial and whether it's being used alone or in combination with other treatments:

• When used as monotherapy, doses are being studied in a range, with some trials examining once-daily (QD) or twice-daily (BID) administration ^[2]
• In combination therapy studies, dosages of 20mg/day, 30mg/day, or 40mg/day are being evaluated ^[4]
• Treatment is typically organized in cycles, often 28-day cycles for monotherapy and combination therapy with various drugs ^[3]

The optimal dosage and administration schedule will be determined based on the results of ongoing clinical trials ^[1].